Acu-URO17 Bladder Cancer Biomarker:

Recognized by the FDA as a “Breakthrough Device”, Acu-URO17 works in conjunction with urine cytology and / or FISH to improve the diagnosis of and management of bladder cancer, while potentially adding a significant new revenue stream. Actively being ordered by and incorporated into urology practices / pathology labs nationwide.

Clinical Utilization (Risk Stratification Tool):

• 99% NPV: RULE OUT – offset cytology’s low sensitivity (~35%) and confirm negative results. Adjudicate atypical diagnoses, identify patients at low risk of bladder cancer, avoid unnecessary testing / procedures
• 96% Sensitivity: RULE IN – patients with confirmed abnormalities and in need of additional testing and work-up
• Unlike cytology and FISH, URO17 detects both low-and high-grade disease
• Numerous published studies available upon request

New Revenue Stream:

• Can immediately be incorporated into a practice’s pathology lab and interpreted by a pathologist

In Network & Cost Effective:

• URO17 CPT 88360 = $119 (CMS)
• For comparison, Urine Cytology CPT 88112 = $68 (CMS)
• Costs significantly less than comparable tests on the market